Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
复制标题
DOI：
10.1016/j.eururo.2008.01.082
复制
发表时间：
2008-11-01
期刊：
影响因子：
23.4
通讯作者：
De Placido, Sabino
中科院分区：
文献类型：
--
作者：
Di Lorenzo, Giuseppe;Figg, William D.;De Placido, Sabino
目的：虽然紫杉烷类药物是转移性难治性前列腺癌（HRPC）一线治疗的最有效药物，但大多数患者在接受紫杉烷类药物治疗时最终会发生进展。没有药物被批准用于HRPC的二线治疗，但肿瘤学家的常见标准做法是在多西他赛失败后也治疗患者。（10 mg/kg）和多西他赛（60 mg/m2）每3 wk一次，所有患者均有骨转移，8例有可测量的病灶。11例患者（55%）有主要前列腺特异性抗原（PSA）缓解，3例（37.5%）有客观缓解。在报告一线多西他赛治疗后PSA下降>50%的同一患者中记录了7例主要PSA缓解。然而，在既往对多西他赛单药治疗无效的患者中观察到4种主要PSA缓解。治疗耐受性良好。结论：我们的研究结果表明，贝伐单抗和多西他赛的组合是积极的，耐受性良好。在HRPC中，需要继续研究贝伐珠单抗联合细胞毒化疗。(C)2008年欧洲泌尿外科协会。Elsevier B. V.出版，保留所有权利。
Objective: Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure.Methods: Twenty highly pretreated patients with HRPC received bevacizumab (10 mg/kg) and docetaxel (60 mg/m(2)) every 3 wk, All patients had bone metastases and eight had measurable lesions.Results: Eleven patients (55%) had major prostate-specific antigen (PSA) responses, and 3 (37.5%) had objective responses. Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. The treatment was well tolerated.Conclusions: Our results show that the combination of bevacizumab and docetaxel is active and well tolerated. Continued investigation of bevacizumab with cytotoxic chemotherapy is warranted in HRPC. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.